PMC9093648_01
Inferonasal corneal ulceration with adjacent inflammation of the left eye.
fmed-09-836873-g0001.jpg
PMC9093648_01_fmed-09-836873-g0001.jpg
F1
She was found to have a perforation within the area of thinning with a flat anterior chamber (Figure 1).
(A) 1-month post-op image showing integration of the amniotic membrane patch in the inferonasal corneal stroma. (B) 3-month post-op image demonstrating smooth integration and an uninflamed left eye.
fmed-09-836873-g0002.jpg
PMC9093648_01_fmed-09-836873-g0002.jpg
F2
The AM patch integrated well into the corneal stroma at the 1-month postoperative visit with Snellen visual acuity of 6/15 and a quiet ocular surface (Figure 2A). Her uncorrected Snellen visual acuity improved to 6/9 at 3-months post op (Figure 2B).
PMC9093648_02
(A) Pre-operative image of the right eye with temporal thinning and perforation, iris prolapse and surrounding inflammation. (B) pre-operative image of the left eye with temporal thinning and surrounding inflammation but no corneal perforation.
fmed-09-836873-g0003.jpg
PMC9093648_02_fmed-09-836873-g0003.jpg
F3
LE), with RE corneal perforation of 2 mm with iris prolapse and LE thinning of ~80-90% within the area of ulceration (Figures 3A,B). RE Anterior chamber was almost flat with 3+ cells and a fibrinous reaction. LE anterior chamber was deep with 2+ cells.
1-month post-op image showing integration of the amniotic membrane patch in the temporal corneal stroma of the right eye (A) and the left eye (B). 3-month post-op image showing uninflamed eyes and a smooth integration of the amniotic membrane patch in the temporal corneal stroma of the right eye (C) and the left eye (D).
fmed-09-836873-g0004.jpg
PMC9093648_02_fmed-09-836873-g0004.jpg
F4
Snellen visual acuity at the 1-month postoperative visit was 6/90 in RE (with cataract) and 6/9 in LE with normal intraocular pressures and a quiet ocular surface (Figures 4A,B). At the 4-month post-operative visit the patient had similar visual acuity, and was maintained on topical preservative free lubricants and Mycophenolate 500 mg BD (Figures 4C,D).